EOC
MCID: OVR094
MIFTS: 39

Ovarian Epithelial Cancer (EOC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 53 29 6
Epithelial Ovarian Cancer 53 73
Ovarian Epithelial Carcinoma 53
Ovarian Cancer, Epithelial 53
Eoc 53

Classifications:



External Ids:

UMLS 73 C0677886

Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to ovarian cancer and adenocarcinoma. An important gene associated with Ovarian Epithelial Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Sensipar and Xgeva have been mentioned in the context of this disorder. Affiliated tissues include t cells, ovary and bone.

Related Diseases for Ovarian Epithelial Cancer

Diseases related to Ovarian Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 30.0 H19 HAGLR HOTAIR MALAT1 MEG3 PIK3CA
2 adenocarcinoma 30.0 H19 MALAT1 PIK3CA
3 retinoblastoma 29.3 HOTAIR MALAT1 MEG3
4 lung cancer 29.0 H19 HAGLR HOTAIR MALAT1 MEG3 PIK3CA
5 ovarian clear cell carcinoma 11.4
6 ovarian cancer 1 11.2
7 ovary transitional cell carcinoma 11.1
8 thrombocytosis 10.3
9 ovarian cyst 10.3
10 fallopian tube carcinoma 10.2
11 primary peritoneal carcinoma 10.1
12 pancreatic neuroendocrine tumor 10.1 MEG3 PIK3CA
13 sclerosing cholangitis, neonatal 10.1
14 endometriosis of ovary 10.1
15 vulva squamous cell carcinoma 10.0 MALAT1 MEG3
16 respiratory system cancer 10.0 MALAT1 PIK3CA
17 meningioma, radiation-induced 10.0 H19 MEG3
18 insulin-like growth factor i 10.0
19 wiskott-aldrich syndrome 10.0
20 wilms tumor 6 10.0
21 diabetes mellitus 10.0
22 leukemia 10.0
23 clear cell adenocarcinoma 10.0
24 silver-russell syndrome 10.0 H19 MEG3
25 functionless pituitary adenoma 10.0 HOTAIR MEG3
26 tongue squamous cell carcinoma 10.0 MALAT1 MEG3
27 esophagus squamous cell carcinoma 9.9 HOTAIR MEG3
28 triple-receptor negative breast cancer 9.9 HOTAIR MALAT1
29 choriocarcinoma 9.9 H19 MALAT1
30 adrenocortical carcinoma, hereditary 9.9 H19 PIK3CA
31 breast cancer 9.8
32 multiple sclerosis 9.8
33 polykaryocytosis inducer 9.8
34 thrombophilia due to thrombin defect 9.8
35 down syndrome 9.8
36 wilms tumor 1 9.8
37 xeroderma pigmentosum, variant type 9.8
38 sarcoma, synovial 9.8
39 aging 9.8
40 myocardial infarction 9.8
41 human immunodeficiency virus type 1 9.8
42 hearing loss, cisplatin-induced 9.8
43 pancreas adenocarcinoma 9.8
44 thrombosis 9.8
45 pelvic inflammatory disease 9.8
46 lactose intolerance 9.8
47 sarcoma 9.8
48 chlamydia 9.8
49 hyperandrogenism 9.8
50 patulous eustachian tube 9.8

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

Drugs & Therapeutics for Ovarian Epithelial Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Sensipar 18 CINACALCET HYDROCHLORIDE Amgen March 2004
2
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
3
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 655)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peppermint Approved Phase 4
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
5
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
6
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
7
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
8
Ferrous fumarate Approved Phase 4,Not Applicable,Early Phase 1 141-01-5
9
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 763113-22-0 23725625
10
Tranexamic Acid Approved Phase 4 1197-18-8 5526
11
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 6918365 151165
12
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
13
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
14
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 5785 54670067
15
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 11103-57-4, 68-26-8 445354
16
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
17
Substance P Investigational Phase 4,Phase 2,Not Applicable 33507-63-0 44359816
18 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Hemostatics Phase 4,Phase 2,Not Applicable
47 Coagulants Phase 4,Phase 2,Not Applicable
48 Antifibrinolytic Agents Phase 4
49 Neurokinin-1 Receptor Antagonists Phase 4,Phase 2,Not Applicable
50 neurokinin A Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2384)
# Name Status NCT ID Phase Drugs
1 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
2 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
3 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
5 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
6 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
7 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
8 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
9 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
10 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
11 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
12 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
13 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Active, not recruiting NCT02476968 Phase 4 Olaparib
14 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
15 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
16 NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. Not yet recruiting NCT03752216 Phase 4 Niraparib
17 Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
18 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
19 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
20 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
21 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
22 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
23 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
24 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
25 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
26 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
27 Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
28 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
29 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
30 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
31 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
32 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
33 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
34 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
35 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
36 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
37 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
38 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
39 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed NCT01847274 Phase 3 Active comparator: Niraparib;placebo
40 Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
41 High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
42 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
43 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
44 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
45 Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
46 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
47 Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy Completed NCT00004166 Phase 3 amifostine trihydrate
48 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
49 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
50 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan

Search NIH Clinical Center for Ovarian Epithelial Cancer

Genetic Tests for Ovarian Epithelial Cancer

Genetic tests related to Ovarian Epithelial Cancer:

# Genetic test Affiliating Genes
1 Ovarian Epithelial Cancer 29

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

41
T Cells, Ovary, Bone, Bone Marrow, Testes, Lung, Endothelial

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 835)
# Title Authors Year
1
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. ( 29454514 )
2018
2
Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer. ( 30111860 )
2018
3
Impact of diabetes mellitus on epithelial ovarian cancer survival. ( 30541490 )
2018
4
Epithelial Ovarian Cancer with Endometriosis is not Associated with Menopausal Status: a Co-Association Study at Prapokklao Hospital ( 29802696 )
2018
5
LncRNA myocardial infarction-associated transcript promotes cell proliferation and inhibits cell apoptosis by targeting miR-330-5p in epithelial ovarian cancer cells. ( 30393480 )
2018
6
Quantitative assessment of serum heat shock protein 27 for the diagnosis of epithelial ovarian cancer using targeted proteomics coupled with immunoaffinity enrichment. ( 30502327 )
2018
7
Distinct Clinical Courses of Epithelial Ovarian Cancer with Mutations in BRCA1 5' and 3' Exons. ( 30504414 )
2018
8
Correction: Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. ( 30513122 )
2018
9
Prognostic Characteristics of MACC1 Expression in Epithelial Ovarian Cancer. ( 30515418 )
2018
10
Diffusion-weighted imaging and diffusion kurtosis imaging for early evaluation of the response to docetaxel in rat epithelial ovarian cancer. ( 30518386 )
2018
11
Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. ( 30518816 )
2018
12
Prognostic Influence of the Time Interval between Surgery and Chemotherapy in Epithelial Ovarian Cancer. ( 30519317 )
2018
13
ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer. ( 30519337 )
2018
14
LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1. ( 30521500 )
2018
15
Downregulation of miR-1294 associates with prognosis and tumor progression in epithelial ovarian cancer. ( 30536306 )
2018
16
Management of epithelial ovarian cancer. ( 30543594 )
2018
17
TNFAIP8 promotes cell growth by regulating the Hippo pathway in epithelial ovarian cancer. ( 30546405 )
2018
18
Circular RNA ITCH suppresses proliferation and promotes apoptosis in human epithelial ovarian cancer cells by sponging miR-10a-α. ( 30556849 )
2018
19
Increased expression of long noncoding RNA HMMR-AS1 in epithelial ovarian cancer: an independent prognostic factor. ( 30556852 )
2018
20
MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer. ( 30557834 )
2018
21
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. ( 30444904 )
2018
22
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. ( 30451713 )
2018
23
Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer. ( 30453728 )
2018
24
Apparent Diffusion Coefficient Histogram Analysis for Assessing Tumor Staging and Detection of Lymph Node Metastasis in Epithelial Ovarian Cancer: Correlation with p53 and Ki-67 Expression. ( 30456593 )
2018
25
Relationship of WNT4 Gene with the Risk of Epithelial Ovarian Cancer: A Han Chinese Population-Based Association Study. ( 30457351 )
2018
26
Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer. ( 30463683 )
2018
27
Combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as a treatment for recurrent epithelial ovarian cancer-National Cancer Institute experience. ( 30470604 )
2018
28
MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods. ( 30471200 )
2018
29
Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. ( 30475821 )
2018
30
Prognostic significance of supradiaphragmatic lymph node metastasis detected by 18F-FDG PET/CT in advanced epithelial ovarian cancer. ( 30477469 )
2018
31
Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff? ( 30479095 )
2018
32
Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer. ( 30371563 )
2018
33
Long non-coding RNA LINC00460 promotes epithelial ovarian cancer progression by regulating microRNA-338-3p. ( 30372802 )
2018
34
Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. ( 30383866 )
2018
35
Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer. ( 30390760 )
2018
36
Management and Treatment of Recurrent Epithelial Ovarian Cancer. ( 30390768 )
2018
37
Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. ( 30395153 )
2018
38
Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer. ( 30396909 )
2018
39
Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer. ( 30396979 )
2018
40
Increased expression of Na+/H+ exchanger isoform 1 predicts tumor aggressiveness and unfavorable prognosis in epithelial ovarian cancer. ( 30405813 )
2018
41
Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening. ( 30303916 )
2018
42
Ovarian stromal cells as a source of cancer-associated fibroblasts in human epithelial ovarian cancer: A histopathological study. ( 30304016 )
2018
43
Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review. ( 30304728 )
2018
44
Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study. ( 30309325 )
2018
45
Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer. ( 30310317 )
2018
46
Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer. ( 30313031 )
2018
47
Does Neoadjuvant Chemotherapy Impact Prognosis in Advanced-Stage Epithelial Ovarian Cancer Optimally Debulked at Surgery? ( 30316718 )
2018
48
Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients. ( 30319054 )
2018
49
Long non‑coding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer. ( 30320385 )
2018
50
CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer. ( 30324802 )
2018

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
2 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
3 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
4 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
5 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
6 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
7 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

Pathways related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR MEG3

GO Terms for Ovarian Epithelial Cancer

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....